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Abstract 
Small cell carcinoma of the uterine cervix is a
rare  form  of  cervical  cancer  characterized  by
extreme  aggressiveness  and  poor  prognosis
because  of  its  rapid  growth,  frequent  distant
metastases,  and  resistance  to  conventional
treatment modalities. We report here a case of
advanced-stage small cell carcinoma of the uter-
ine cervix treated by neoadjuvant chemotherapy,
followed by radical surgery, resulting in locore-
gional disease control. A 39-year-old Japanese
woman was diagnosed as having stage IIIb small
cell carcinoma of the uterine cervix. She was
treated  by  neoadjuvant  chemotherapy  with
irinotecan/cisplatin, followed by extended radi-
cal hysterectomy with pelvic and paraaortic lym-
phadenectomy. The patient was further treated
by adjuvant chemotherapy with irinotecan/cis-
platin.  Intra  pelvic  recurrence  has  not  been
detected  throughout  the  postoperative  course.
However, the patient died with distant metas-
tases of the disease, 27 months following the ini-
tial treatment. It has been suggested that neoad-
juvant chemotherapy therapy followed by radical
surgery is a treatment option for advanced-stage
small cell carcinoma of the uterine cervix for the
locoregional disease control. Further studies are
necessary to obtain information regarding mul-
timodal treatment including sequence, duration,
frequency, and type of effective chemotherapy
agents to be used in the treatment of small cell
carcinoma of the uterine cervix.
Introduction
Small cell carcinoma is the most common
neuroendocrine tumor of the uterine cervix. It
has  been  estimated  that  it  may  account  for
approximately  0.3-3%  of  all  cervical  carcino-
mas.1-12 The clinical behavior of small cell car-
cinoma of the uterine cervix is similar to that
of small cell carcinoma of the lung,5,6 and dif-
fers from the more commonly seen squamous
cell or adenocarcinoma of the cervix. Small cell
carcinoma of the uterine cervix is usually not
confined to the cervix at the time of diagnosis,
as it tends to spread to bone, brain, lung, and
liver tissues.2,11,12
It is extremely aggressive and has an unfa-
vorable outcome, due to the early development
of lymph node and distant organ metastases
and vascular invasion.1-3, 5,7,10,11 An optimal ini-
tial therapeutic approach to this rare disease,
especially at an advanced stage, has not yet
been clearly defined. However, it has been gen-
erally accepted that small cell carcinoma of the
uterine cervix should be treated by multidisci-
plinary therapy, including surgery, chemother-
apy, and radiotherapy.2-4,6,12,13 In this report, a
case of advanced-stage small cell carcinoma of
the  uterine  cervix  treated  with  neoadjuvant
chemotherapy, followed by radical surgery and
adjuvant chemotherapy is described. Current
strategies for the multimodal treatment of this
rare tumor type are also discussed. 
Case Report
A 39-year-old Japanese woman (gravida 3,
para  1)  was  admitted  complaining  of  lower
abdominal  pain.  Gynecological  and  rectal
examinations  showed  macroscopic  cervical
cancer (6 cm in diameter), which had infiltrat-
ed  to  the  pelvic  wall.  Bilateral  inguinal  and
femoral  lymph  nodes  were  not  evident.  The
pathological diagnosis of a punch biopsy taken
from the uterine cervix was primary small cell
carcinoma (Figure 1). No distant metastasis
was detected by chest X-ray, intravenous pyelo-
gram,  cystoscopy,  or  colon  fiberscopy.
Computed tomography (CT) and magnetic res-
onance imaging (MRI) revealed an enlarged
uterine cervix (64×58×64 mm) and paraaortic
and pelvic lymph node metastases (Figure 2A).
Serum level of tumor markers were as follows:
neuron-specific  enolase  (NSE),  12.9  ng/mL
(<10  ng/mL);  pro  gastrin-releasing  peptide
(GRP), 398 pg/mL (<46.0 pg/mL); squamous
cell  carcinoma  antigen,  1.3  ng/mL  (<1.5
ng/mL);  and  Cyfra  21-1,  1.4  ng/mL  (<2.3
ng/mL). The patient was diagnosed with stage
IIIb uterine cervical cancer, according to the
International Federation of Gynecologists and
Obstetricians  (FIGO)  classification  system
(1994). The patient had also previously been
diagnosed with type 2 diabetes mellitus. 
Immediately  after  the  cancer  diagnosis,
neoadjuvant  chemotherapy  with  irinotecan 
(60  mg/m2,  days  1,  8,  and  15)  and  cisplatin 
(60 mg/m2, day 1). After 2 courses of irinote-
can/cisplatin,  the  size  of  the  cervical  tumor
had  significantly  decreased  (54%  decrease)
(Figure 2B). Paraaortic and pelvic lymph nodal
swelling had also decreased. Subsequently the
patient underwent extended radical hysterec-
tomy with pelvic and paraaortic (below the ori-
gin  of  the  inferior  mesenteric  artery)  lym-
phadenectomy.  Pathologically,  viable  tumor
cells were identified in the uterine cervix and
in  numerous  paraaortic  and  pelvic  lymph
nodes. 
Subsequently, adjuvant chemotherapy with
irinotecan/cisplatin, which was effective in the
neoadjuvant setting, was reintroduced. After 5
courses  of  postoperative  chemotherapy  with
irinotecan/cisplatin,  tumor  recurrence  was
identified  in  the  paraaortic  lymph  nodes.
Second-line  chemotherapy  with  amrubicin 
(45 mg/m2, day 1-3, 21 day-cycle) was started.
The lymph node swelling disappeared after 2
courses  of  amrubicin.  However,  the  tumor
recurred  again  after  a  total  of  7  courses  of
chemotherapy  with  amrubicin  (13  months
after initial treatment). Carboplatin/etoposide
was  used  as  third-line  chemotherapy.  No
severe  side  effects  associated  with  irinote-
can/cisplatin,  amrubicin,  and  carboplatin/
etoposide were observed. The patient died of
disease progression 27 months following the
initial  treatment.  No  intrapelvic  recurrence
was detected by pelvic examination or by stan-
dard imaging modalities including transvagi-
nal ultrasonography, CT, and MRI, throughout
the postoperative course. 
Discussion
Small cell carcinoma of the uterine cervix is
associated with a poor prognosis even after the
administration  of  multimodal  therapy.8,9,11,12
This  rare  disease  tends  toward  rapid
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extrapelvic distant metastasis to areas such as
the lung, liver, brain, bone and lymph nodes,
resulting in a shorter overall survival time than
that seen in patients with other histopatholog-
ical  subtypes  of  cervical  carcinoma.1,2,4,9,11,12
Hoskins et al.2 reported that 73% of patients at
presentation have evidence of extrapelvic dis-
ease, which correspond to 3-year survival rates
of only 28%. Other studies have noted 5-year
survival  rates  ranging  from  0-60%  for  early-
stage disease, and 0-17% for advanced-stage
disease.1,6,12 It  has  been  proposed  that
advanced  stage,  large  tumor  size,  margin
involvement, positive lymph nodes, pure histol-
ogy, margin status, polypoid pattern, and smok-
ing were poor prognostic factors.1-3,5,6,8,11,14
The treatment of small cell carcinoma of the
uterine cervix is essentially extrapolated from
that for small cell lung cancer. However, the
optimal initial therapeutic approach to small
cell carcinoma of the uterine cervix in particu-
lar  has  not  yet  been  clearly  defined.
Locoregional treatment alone has been report-
ed as insufficient, in most patients, to control
both the local and distant aggressiveness of
the  disease.1,11,12 It  has  been  suggested  that
small  cell  carcinoma  of  the  uterine  cervix
should be treated by multidisciplinary therapy,
including  surgery,  chemotherapy,  and  radio-
therapy.2-4,6,11-13 Patients receiving initial con-
current chemoradiotherapy with surgery may
fare  better,  although  the  evidence  remains
inconclusive.4,7,11,12 Locoregional  recurrence
outside irradiated fields is frequently observed
in patients treated by radiotherapy.8 Therefore,
additional treatment strategy for locoregional
disease control is necessary. Recently, neoad-
juvant  or  postoperative  chemotherapy  has
been used in an attempt to improve the sur-
vival of patients with small cell carcinoma of
the uterine cervix.2,3,13,15
Some trials have revealed improved onco-
logic outcomes when patients are treated with
similar regimens to those used for small cell
cancers of the lung.7 Hoskins et al.7 reported
encouraging  results  using  concurrent
chemoradiation in patients with advanced dis-
ease. The patients were treated with protocols
including  etoposide,  cisplatin,  and  radiation
therapy  with  concurrent  chemotherapy,  and
with or without the addition of carboplatin and
paclitaxel. Prophylactic cranial radiation was
optional.  Interestingly,  after  a  high  rate  of
paraaortic  metastases  was  noted  in  these
patients, the authors also began to include rou-
tine paraaortic irradiation in their protocol. In
their  analysis,  the  3-year  survival  rate  of
patients with advanced disease was 38%. The
rarity of this tumor type renders it difficult to
perform randomized controlled trials. Thus, in
spite  of  established  treatment  regimens,  an
optimal  therapeutic  approach  to  treating
advanced cases of this disease has yet to be
determined.6
Several  combination  chemotherapy  regi-
mens have been demonstrated to achieve bet-
ter survival for patients primarily treated with
surgery for small cell carcinoma of the uterine
cervix.1,3,6 Most  frequently  used  regimens
include etoposide/cisplatin,2-4 and, carboplatin/
paclitaxel.7 However, the aggressiveness and
poor prognosis of small cell carcinoma of the
uterine  cervix  suggest  the  need  for  novel
chemotherapy regimens. As demonstrated in
the  present  report,  irinotecan/cisplatin  and
amrubicin, which are currently used for the
small cell lung cancer,16-18 are considered to be
effective for small cell carcinoma of the uterine
cervix. Favorable results have been reported in
patients with small cell carcinoma of the uter-
Case Report
Figure 1. Magnetic resonance imaging findings at initial diagnosis (A) and after 2 cours-
es of neoadjuvant chemotherapy (B). (A) Magnetic resonance imaging at initial diagno-
sis revealed an enlarged uterine cervix (64¥58 mm). (B) After 2 courses of neoadjuvant
chemotherapy, a significant decrease in tumor size was achieved. 
Figure 2. Immunohistological findings of the biopsied specimen. A, H&E; B, MNF116;
C, chromogranin A; D, TTF-1 (original magnification ¥400). The tumor showed typical
features of small cell carcinoma. The tumor was densely cellular and showed trabecular
nesting or a sheet-like pattern. The nuclei of the tumor cells were hyperchromatic. The
cells had scant cytoplasm, round nuclei, an absence of nucleoli, and finely dispersed
chromatin closely resembling the cells of oat cell carcinoma of the lung. Nuclear mold-
ing, single cell necrosis, and high mitotic activity were seen in all tumors. No areas of
glandular or squamous differentiation were identified. Immunostaining revealed that the
tumor cells were positive for MNF116 and chromogranin A, and negative for TTF-1. [page 20] [Rare Tumors 2011; 3:e6]
ine cervix who received concurrent chemoradi-
ation followed by adjuvant chemotherapy,7,8, 11,12
while other studies have reported that radical
surgery is an important component in the mul-
timodal treatment of small cell carcinoma of
the uterine cervix.5,14 In cases involving adju-
vant chemotherapy following surgery, the delay
in systemic treatment resulting from even a
short postsurgical recovery period might place
a patient at risk for metastatic spread. For this
reason, Lewandowski and Copeland 13 proposed
the use of neoadjuvant chemotherapy followed
by surgery and or radiation therapy for the treat-
ment of neuroendocrine tumors of the cervix. It
has  also  been  recommended  neoadjuvant
chemotherapy  for  patients  with  large-sized
tumors,  which  is  expected  to  enhance  the
resectability  of  the  bulky  tumors  and  thereby
improve outcomes.5-7,14
In conclusion, we reported here a case of
advanced-stage  small  cell  carcinoma  of  the
uterine  cervix  treated  with  neoadjuvant
chemotherapy followed by radical surgery and
adjuvant chemotherapy, which yielded success-
ful  locoregional  disease  control.  Although  to
date there have been no randomized clinical
trials to evaluate this approach, our multimodal
treatment strategy is suggested to be an impor-
tant component for this aggressive disease.  
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